Jennifer Lee is the Executive Vice President and Head of North America at Rhythm Pharmaceuticals Inc., a biopharmaceutical company focused on developing and commercializing therapies for rare genetic disorders of obesity. In her role, Jennifer oversees the company's operations and strategic initiatives in the North American market, driving the growth and expansion of Rhythm's innovative treatments. With over two decades of experience in the biopharmaceutical industry, Jennifer has a proven track record of leadership and success. Prior to joining Rhythm Pharmaceuticals, she held senior positions at several prominent companies, including Vertex Pharmaceuticals and Novartis. At Vertex, Jennifer played a key role in the successful launch and commercialization of groundbreaking cystic fibrosis treatments, demonstrating her ability to navigate complex markets and deliver life-changing therapies to patients. Her strategic vision and deep understanding of the rare disease landscape have been instrumental in positioning Rhythm Pharmaceuticals as a leader in the field of genetic obesity disorders. Under Jennifer's leadership, Rhythm Pharmaceuticals has made significant strides in advancing its mission to address the unmet needs of patients with rare genetic disorders. She has been instrumental in building a strong commercial organization, fostering partnerships with key stakeholders, and driving the successful launch of setmelanotide, the company's first FDA-approved treatment for certain rare genetic disorders of obesity. Jennifer's dedication to improving patient outcomes and her passion for innovation make her a valuable asset to Rhythm Pharmaceuticals as the company continues to expand its reach and impact in the North American market.